Ranchi News Desk

Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex

 Breaking News
  • No posts were found

Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex

September 07
01:10 2023
Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Cystic Fibrosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.

 

Some of the key takeaways from the Cystic Fibrosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years. 
  • Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment 
  • Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.   
  • In September 2021, In order to assess the effectiveness and safety of VX-121 combination therapy in patients with cystic fibrosis (cf) who are heterozygous for f508del and a minimal function mutation (F/MF), Vertex Pharmaceuticals started a Phase III, randomised, double-blind, controlled research. This study’s goal is to assess VX-121/tezacaftor/deutivacaftor’s (VX-121/TEZ/D-IVA) effectiveness and safety in CF patients who are heterozygous for F508del and a minimal function mutation (F/MF patients).
  • In May 2021, Vertex Pharmaceuticals Incorporated purchased the potential future milestones related to VX-561 (deutivacaftor) under the firms’ 2017 asset purchase agreement for $32 million, according to an announcement from Concert Pharmaceuticals.

 

Cystic Fibrosis Overview

A mutation in the epithelial chloride channel protein CFTR leads to the genetic condition known as cystic fibrosis (CF), which is a recessive condition. The severity of CF, a hereditary illness that predominates, can range from moderate to life-threatening.

 

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline

 

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:

  • SP-101: Spirovant Sciences
  • LUNAR CF: Arcturus Therapeutics
  • KB407: Krystal Biotech
  • VX-522: Vertex Pharmaceuticals
  • Galicaftor/Navoc aftor/ABBV-576: AbbVie
  • AP-PA02: Armata Pharmaceuticals
  • 4D-710: 4D Molecular Therapeutics
  • ELX-02: Eloxx Pharmaceutical
  • Ensifentrine: Verona Pharma
  • Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals
  • OligoG: Algi Pharma
  • MRT5005: Translate Bio
  • CB280: Calithera Biosciences
  • KB407 : Krystal Biotech
  • SPL84231: SpliSense

 

Cystic Fibrosis Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

 

Cystic Fibrosis Molecule Type

Cystic Fibrosis Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

 

Cystic Fibrosis Pipeline Therapeutics Assessment

  • Cystic Fibrosis Assessment by Product Type
  • Cystic Fibrosis By Stage and Product Type
  • Cystic Fibrosis Assessment by Route of Administration
  • Cystic Fibrosis By Stage and Route of Administration
  • Cystic Fibrosis Assessment by Molecule Type
  • Cystic Fibrosis by Stage and Molecule Type

 

DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies

 

Cystic Fibrosis Pipeline Analysis:

The Cystic Fibrosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
  • Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies

 

Cystic Fibrosis Pipeline Market Drivers

  • Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.

 

Cystic Fibrosis Pipeline Market Barriers

  • However, no standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.

 

Scope of Cystic Fibrosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others
  • Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others
  • Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
  • Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers 

 

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials

 

Table of Contents 

1. Cystic Fibrosis Report Introduction

2. Cystic Fibrosis Executive Summary

3. Cystic Fibrosis Overview

4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cystic Fibrosis Pipeline Therapeutics

6. Cystic Fibrosis Late Stage Products (Phase II/III)

7. Cystic Fibrosis Mid Stage Products (Phase II)

8. Cystic Fibrosis Early Stage Products (Phase I)

9. Cystic Fibrosis Preclinical Stage Products

10. Cystic Fibrosis Therapeutics Assessment

11. Cystic Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cystic Fibrosis Key Companies

14. Cystic Fibrosis Key Products

15. Cystic Fibrosis Unmet Needs

16 . Cystic Fibrosis Market Drivers and Barriers

17. Cystic Fibrosis Future Perspectives and Conclusion

18. Cystic Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services